Kiora Pharmaceuticals (KPRX) Short Interest Ratio & Short Volume

Short interest is the volume of Kiora Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 66,500 shares of KPRX short. 0.28% of Kiora Pharmaceuticals' shares are currently sold short. Learn More on Kiora Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.28% of Kiora Pharmaceuticals' floating shares are currently sold short.

Kiora Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 66,500 shares, a drop of 50.7% from the previous total of 135,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Kiora Pharmaceuticals currently has issued a total of 26,260,000 shares. Some of Kiora Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Kiora Pharmaceuticals currently has a public float of 23,950,000 shares.

0.28% of Kiora Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Kiora Pharmaceuticals: Jaguar Health, Inc. (4.32%), Carisma Therapeutics, Inc. (7.78%), Rockwell Medical, Inc. (2.11%), Anebulo Pharmaceuticals, Inc. (0.07%), Tharimmune, Inc. (0.17%), Kezar Life Sciences, Inc. (5.10%), Equillium, Inc. (1.61%), Eagle Pharmaceuticals, Inc. (9.97%), CASI Pharmaceuticals, Inc. (0.83%), Aadi Bioscience, Inc. (5.54%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling KPRX is an investing strategy that aims to generate trading profit from Kiora Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Kiora Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KPRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KPRX, twice per month. The most recent reporting period available is May, 15 2024.